Silver Studies Source References From The National Institutes of Health Website

June 7, 2020; By Ben Taylor;  Silver Bulletin; The use of the noble mineral silver in various forms as a natural anti-microbial agent has a history known to be at least 6,000 years old. This well established historical fact is even documented on Pub Med Central (PMC), US National Library of Medicine, National Institutes of Health.

The article is titled under “Surgical Infections”: “Use of Silver in the Prevention and Treatment of Infections: Silver Review”. The article is rather lengthy and although not directly and overtly endorsing the use of silver, it actually presents a balanced abstract about the use of silver in preventing and healing infections, as well as what they consider adverse effects. Just as interesting as the abstract is the extensive list of 188 References which includes reviews, history accounts, mechanistic studies, clinical studies and experiences, prospective comparisons, randomized trials, in vitro and in vivo evaluations, studies of inhibitory and therapeutic effects, systematic review of silver-releasing dressings, randomized controlled trial and cost-effectiveness analysis, clinical trials, randomized crossover studies, impact studies, surface coating studies, pathologic analysis, and the list goes on. So if anyone tells you there are no silver studies, clinical or otherwise, simply show them this article link and its source references from the governmental corporation website of the National Institutes of Health.

These are simply a few silver based studies that are referenced on the NIH website. There are many more as we have also posted on other pages. But when some pharmakeia/drug pushing lackey with the pharma-industrial complex or their partners-in-criminal conspiracy against natural healhcare and the People of America in some corporate agency says there are no credible silver studies, you will know they are lying. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955599/

Source References:

  1. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10:289–292. [PubMed] [Google Scholar]
  2. Klasen HJ. Historical review of the use of silver in the treatment of burns I: Early uses. Burns. 2000;26:117–130. [PubMed] [Google Scholar]
  3. Klasen HJ. A historical review of the use of silver in the treatment of burns II: Renewed interest for silver. Burns. 2000;26:131–138. [PubMed] [Google Scholar]
  4. Reid MR. Zinninger MM. Merrell P. Closure of the abdomen with through-and-through silver wire sutures in cases of acute abdominal emergencies. Ann Surg. 1933;98:890–896. [PMC free article] [PubMed] [Google Scholar]
  5. Rucker MP. Silver sutures. Bull Hist Med. 1950;24:190–192. [PubMed] [Google Scholar]
  6. Clement JL. Jarrett PS. Antibacterial silver. Met Based Drugs. 1994;1:467–482. [PMC free article] [PubMed] [Google Scholar]
  7. Fox CL., Jr Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974;5:582–588. [PMC free article] [PubMed] [Google Scholar]
  8. Monafo WW. The management of burns II: The silver nitrate method. Curr Probl Surg. 1969;Feb:53–66. [PubMed] [Google Scholar]
  9. Feng QL. Wu J. Chen GQ, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res. 2000;52:662–668. [PubMed] [Google Scholar]
  10. Rosenkranz HS. Rosenkranz S. Silver sulfadiazine: Interaction with isolated deoxyribonucleic acid. Antimicrob Agents Chemother. 1972;2:373–383. [PMC free article] [PubMed] [Google Scholar]
  11. Jung WK. Koo HC. Kim KW, et al. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol. 2008;74:2171–2178. [PMC free article] [PubMed] [Google Scholar]
  12. Gordon O. Vig Slenters T. Brunetto PS, et al. Silver coordination polymers for prevention of implant infection: Thiol interaction, impact on respiratory chain enzymes, and hydroxyl radical induction. Antimicrob Agents Chemother. 2010;54:4208–4218. [PMC free article] [PubMed] [Google Scholar]
  13. Schreurs WJ. Rosenberg H. Effect of silver ions on transport and retention of phosphate by Escherichia coli. J Bacteriol. 1982;152:7–13. [PMC free article] [PubMed] [Google Scholar]
  14. Ricketts CR. Lowbury EJ. Lawrence JC, et al. Mechanism of prophylaxis by silver compounds against infection of burns. Br Med J. 1970;1(5707):444–446. [PMC free article] [PubMed] [Google Scholar]
  15. Dunn K. Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns. 2004;30(Suppl 1):S1–S9. [PubMed] [Google Scholar]
  16. Kim JS. Kuk E. Yu KN, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007;3:95–101. [PubMed] [Google Scholar]
  17. Pal S. Tak YK. Joardar J, et al. Nanocrystalline silver supported on activated carbon matrix from hydrosol: Antibacterial mechanism under prolonged incubation conditions. J Nanosci Nanotechnol. 2009;9:2092–2103. [PubMed] [Google Scholar]
  18. Li WR. Xie XB. Shi QS, et al. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85:1115–1122. [PubMed] [Google Scholar]
  19. Xu H. Qu F. Xu H, et al. Role of reactive oxygen species in the antibacterial mechanism of silver nanoparticles on Escherichia coli O157:H7. Biometals. 2011;25:45–53. [PubMed] [Google Scholar]
  20. Morones JR. Elechiguerra JL. Camacho A, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16:2346–2353. [PubMed] [Google Scholar]
  21. Fox CL., Jr Silver sulfadiazine—A new topical therapy for Pseudomonas in burns. Arch Surg. 1968;96:184–188. [PubMed] [Google Scholar]
  22. Stanford W. Rappole BW. Fox CL., Jr Clinical experience with silver sulfadiazine, a new topical agent for control of Pseudomonas infections in burns. J Trauma. 1969;9:377–388. [PubMed] [Google Scholar]
  23. Monafo WW. Moyer CA. The treatment of extensive thermal burns with 0.5 per cent silver nitrate solution. Ann NY Acad Sci. 1968;150:937–945. [PubMed] [Google Scholar]
  24. Price WR. Wood M. Treatment of the infected burn with dilute silver nitrate solution. Am J Surg. 1967;114:641–647. [PubMed] [Google Scholar]
  25. Atiyeh BS. Costagliola M. Hayek SN. Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns. 2007;33:139–148. [PubMed] [Google Scholar]
  26. Helvig EI. Munster AM. Su CT. Oppel W. Cerium nitrate–silver sulfadiazine cream in the treatment of burns: A prospective, randomized study. Am Surg. 1979;45:270–272. [PubMed] [Google Scholar]
  27. Munster AM. Helvig E. Rowland S. Cerium nitrate–silver sulfadiazine cream in the treatment of burns: A prospective evaluation. Surgery. 1980;88:658–660. [PubMed] [Google Scholar]
  28. Bowser BH. Caldwell FT. Cone JB, et al. A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children. J Trauma. 1981;21:558–563. [PubMed] [Google Scholar]
  29. de Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine–cerium nitrate in the treatment of moderate and severe burns. Burns. 2001;27:67–74. [PubMed] [Google Scholar]
  30. Inman RJ. Snelling CF. Roberts FJ, et al. Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection. Burns Incl Therm Inj. 1984;11:35–40. [PubMed] [Google Scholar]
  31. Snelling CF. Inman RJ. Germann E, et al. Comparison of silver sulfadiazine 1% with chlorhexidine digluconate 0.2% to silver sulfadiazine 1% alone in the prophylactic topical antibacterial treatment of burns. J Burn Care Rehabil. 1991;12:13–18. [PubMed] [Google Scholar]
  32. Fraser JF. Bodman J. Sturgess R, et al. An in vitro study of the anti-microbial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulphadiazine cream and a silver coated dressing. Burns. 2004;30:35–41. [PubMed] [Google Scholar]
  33. Gray JH. Henry DA. Forbes M, et al. Comparison of silver sulphadiazine 1 per cent, silver sulphadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent and mafenide acetate 8.5 per cent for topical antibacterial effect in infected full skin thickness rat burn wounds. Burns. 1991;17:37–40. [PubMed] [Google Scholar]
  34. Koller J. Topical treatment of partial thickness burns by silver sulfadiazine plus hyaluronic acid compared to silver sulfadiazine alone: A double-blind, clinical study. Drugs Exp Clin Res. 2004;30:183–190. [PubMed] [Google Scholar]
  35. Costagliola M. Agrosì M. Second-degree burns: A comparative, multicenter, randomized trial of hyaluronic acid plus silver sulfadiazine vs. silver sulfadiazine alone. Curr Med Res Opin. 2005;21:1235–1240. [PubMed] [Google Scholar]
  36. Leaper DJ. Silver dressings: Their role in wound management. Int Wound J. 2006;3:282–294. [PubMed] [Google Scholar]
  37. Cutting K. White R. Hoekstra H. Topical silver-impregnated dressings and the importance of the dressing technology. Int Wound J. 2009;6:396–402. [PubMed] [Google Scholar]
  38. Fong J. Wood F. Nanocrystalline silver dressings in wound management: A review. Int J Nanomedicine. 2006;1:441–449. [PMC free article] [PubMed] [Google Scholar]
  39. Deitch EA. Marino AA. Malakanok V. Albright JA. Silver nylon cloth: In vitro and in vivo evaluation of antimicrobial activity. J Trauma. 1987;27:301–304. [PubMed] [Google Scholar]
  40. Gravante G. Caruso R. Sorge R, et al. Nanocrystalline silver: A systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Ann Plast Surg. 2009;63:201–205. [PubMed] [Google Scholar]
  41. Falcone AE. Spadaro JA. Inhibitory effects of electrically activated silver material on cutaneous wound bacteria. Plast Reconstr Surg. 1986;77:455–459. [PubMed] [Google Scholar]
  42. Becker RO. Spadaro JA. Treatment of orthopaedic infections with electrically generated silver ions: A preliminary report. J Bone Joint Surg Am. 1978;60:871–881. [PubMed] [Google Scholar]
  43. Chu CS. McManus AT. Pruitt BA., Jr Mason AD., Jr Therapeutic effects of silver nylon dressings with weak direct current on Pseudomonas aeruginosa-infected burn wounds. J Trauma. 1988;28:1488–1492. [PubMed] [Google Scholar]
  44. Chu CS. McManus AT. Mason AD. Pruitt BA., Jr Topical silver treatment after escharectomy of infected full thickness burn wounds in rats. J Trauma. 2005;58:1040–1046. [PubMed] [Google Scholar]
  45. Chu CS. Matylevich NP. McManus AT, et al. Optimized mesh expansion of composite skin grafts in rats treated with direct current. J Trauma. 1997;43:804–811. [PubMed] [Google Scholar]
  46. Chu CS. Matylevitch NP. McManus AT, et al. Accelerated healing with a mesh autograft/allodermal composite skin graft treated with silver nylon dressings with and without direct current in rats. J Trauma. 2000;49:115–125. [PubMed] [Google Scholar]
  47. Chu CS. McManus AT. Okerberg CV, et al. Weak direct current accelerates split-thickness graft healing on tangentially excised second-degree burns. J Burn Care Rehabil. 1991;12:285–293. [PubMed] [Google Scholar]
  48. Engrav LH. Heimbach DM. Reus JL, et al. Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: A randomized prospective study. J Trauma. 1983;23:1001–1004. [PubMed] [Google Scholar]
  49. Barret JP. Dziewulski P. Ramzy PI, et al. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg. 2000;105:62–65. [PubMed] [Google Scholar]
  50. Hosseini SN. Karimian A. Mousavinasab SN, et al. Xenoderm versus 1% silver sulfadiazine in partial-thickness burns. Asian J Surg. 2009;32:234–239. [PubMed] [Google Scholar]
  51. Gerding RL. Emerman CL. Effron D, et al. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. Ann Emerg Med. 1990;19:121–124. [PubMed] [Google Scholar]
  52. Silverstein P. Heimbach D. Meites H, et al. An open, parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam dressing (intervention) vs silver sulfadiazine cream. J Burn Care Res. 2011;32:617–626. [PubMed] [Google Scholar]
  53. Fong J. Wood F. Fowler B. A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: Comparative patient care audits. Burns. 2005;31:562–567. [PubMed] [Google Scholar]
  54. Vermeulen H. van Hattem JM. Storm-Versloot MN. Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev. 2007;(1):CD005486. [PubMed] [Google Scholar]
  55. Lo SF. Hayter M. Chang CJ, et al. A systematic review of silver-releasing dressings in the management of infected chronic wounds. J Clin Nurs. 2008;17:1973–1985. [PubMed] [Google Scholar]
  56. Chambers H. Dumville JC. Cullum N. Silver treatments for leg ulcers: A systematic review. Wound Repair Regen. 2007;15:165–173. [PubMed] [Google Scholar]
  57. Lo SF. Chang CJ. Hu WY, et al. The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: A meta-analysis. J Clin Nurs. 2009;18:716–728. [PubMed] [Google Scholar]
  58. Carter MJ. Tingley-Kelley K. Warriner RA., 3rd Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: A systematic review and meta-analysis. J Am Acad Dermatol. 2010;63:668–679. [PubMed] [Google Scholar]
  59. Michaels JA. Campbell B. King B, et al. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial) Br J Surg. 2009;96:1147–1156. [PubMed] [Google Scholar]
  60. Scanlon E. Karlsmark T. Leaper DJ, et al. Cost-effective faster wound healing with a sustained silver-releasing foam dressing in delayed healing leg ulcers: A health-economic analysis. Int Wound J. 2005;2:150–160. [PubMed] [Google Scholar]
  61. Wang J. Smith J. Babidge W. Maddern G. Silver dressings versus other dressings for chronic wounds in a community care setting. J Wound Care. 2007;16:352–356. [PubMed] [Google Scholar]
  62. Jørgensen B. Price P. Andersen KE, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: A randomised, controlled trial. Int Wound J. 2005;2:64–73. [PubMed] [Google Scholar]
  63. Münter KC. Beele H. Russell L, et al. Effect of a sustained silver-releasing dressing on ulcers with delayed healing: The CONTOP study. J Wound Care. 2006;15:199–206. [PubMed] [Google Scholar]
  64. Totaro P. Rambaldini M. Efficacy of antimicrobial activity of slow release silver nanoparticles dressing in post-cardiac surgery mediastinitis. Interact Cardiovasc Thorac Surg. 2009;8:153–154. [PubMed] [Google Scholar]
  65. Huckfeldt R. Redmond C. Mikkelson D, et al. A clinical trial to investigate the effect of silver nylon dressings on mediastinitis rates in postoperative cardiac sternotomy incisions. Ostomy Wound Manage. 2008;54:36–41. [PubMed] [Google Scholar]
  66. Krieger BR. Davis DM. Sanchez JE, et al. The use of silver nylon in preventing surgical site infections following colon and rectal surgery. Dis Colon Rectum. 2011;54:1014–1019. [PubMed] [Google Scholar]
  67. Childress BB. Berceli SA. Nelson PR, et al. Impact of an absorbent silver-eluting dressing system on lower extremity revascularization wound complications. Ann Vasc Surg. 2007;21:598–602. [PubMed] [Google Scholar]
  68. Innes ME. Umraw N. Fish JS, et al. The use of silver coated dressings on donor site wounds: A prospective, controlled matched pair study. Burns. 2001;27:621–627. [PubMed] [Google Scholar]
  69. Lohsiriwat V. Chuangsuwanich A. Comparison of the ionic silver-containing hydrofiber and paraffin gauze dressing on split-thickness skin graft donor sites. Ann Plast Surg. 2009;62:421–422. [PubMed] [Google Scholar]
  70. Payne JL. Ambrosio AM. Evaluation of an antimicrobial silver foam dressing for use with V.A.C. therapy: Morphological, mechanical, and antimicrobial properties. J Biomed Mater Res B Appl Biomater. 2009;89:217–222. [PubMed] [Google Scholar]
  71. Gerry R. Kwei S. Bayer L. Breuing KH. Silver-impregnated vacuum-assisted closure in the treatment of recalcitrant venous stasis ulcers. Ann Plast Surg. 2007;59:58–62. [PubMed] [Google Scholar]
  72. Cohen MS. Stern JM. Vanni AJ, et al. In vitro analysis of a nanocrystalline silver-coated surgical mesh. Surg Infect. 2007;8:397–403. [PubMed] [Google Scholar]
  73. Chu CC. Tsai WC. Yao JY. Chiu SS. Newly made antibacterial braided nylon sutures I: In vitro qualitative and in vivo preliminary biocompatibility study. J Biomed Mater Res. 1987;21:1281–1300. [PubMed] [Google Scholar]
  74. Pratten J. Nazhat SN. Blaker JJ. Boccaccini AR. In vitro attachment of Staphylococcus epidermidis to surgical sutures with and without Ag-containing bioactive glass coating. J Biomater Appl. 2004;19:47–57. [PubMed] [Google Scholar]
  75. Blaker JJ. Nazhat SN. Boccaccini AR. Development and characterisation of silver-doped bioactive glass-coated sutures for tissue engineering and wound healing applications. Biomaterials. 2004;25:1319–1329. [PubMed] [Google Scholar]
  76. Renaud B. Brun-Buisson C ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia: A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–1590. [PubMed] [Google Scholar]
  77. Blot SI. Depuydt P. Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005;41:1591–1598. [PubMed] [Google Scholar]
  78. Warren DK. Quadir WW. Hollenbeak CS, et al. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006;34:2084–2089. [PubMed] [Google Scholar]
  79. Pittet D. Tarara D. Wenzel RP. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–1601. [PubMed] [Google Scholar]
  80. Dimick JB. Pelz RK. Consunji R, et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136:229–234. [PubMed] [Google Scholar]
  81. O’Grady NP. Alexander M. Burns LA, et al. Healthcare Infection Control Practices Advisory Committee (HICPAC) Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-Related Infections. Clin Infect Dis. 2011;52:1087–1099. [PMC free article] [PubMed] [Google Scholar]
  82. Pronovost P. Needham D. Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725–2732. [PubMed] [Google Scholar]
  83. Dünser MW. Mayr AJ. Hinterberger G, et al. Central venous catheter colonization in critically ill patients: A prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesth Analg. 2005;101:1778–1784. [PubMed] [Google Scholar]
  84. Bach A. Eberhardt H. Frick A, et al. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Crit Care Med. 1999;27:515–521. [PubMed] [Google Scholar]
  85. Corral L. Nolla-Salas M. Ibañez-Nolla J, et al. A prospective, randomized study in critically ill patients using the Oligon Vantex catheter. J Hosp Infect. 2003;55:212–219. [PubMed] [Google Scholar]
  86. Moretti EW. Ofstead CL. Kristy RM. Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. J Hosp Infect. 2005;61:139–145. [PubMed] [Google Scholar]
  87. Maki DG. Stolz SM. Wheeler S. Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: A randomized, controlled trial. Ann Intern Med. 1997;127:257–266. [PubMed] [Google Scholar]
  88. Rupp ME. Lisco SJ. Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: A randomized, controlled trial. Ann Intern Med. 2005;143:570–580. [PubMed] [Google Scholar]
  89. Casey AL. Mermel LA. Nightingale P. Elliott TS. Antimicrobial central venous catheters in adults: A systematic review and meta-analysis. Lancet Infect Dis. 2008;8:763–776. [PubMed] [Google Scholar]
  90. Wang H. Huang T. Jing J, et al. Effectiveness of different central venous catheters for catheter-related infections: A network meta-analysis. J Hosp Infect. 2010;76:1–11. [PubMed] [Google Scholar]
  91. Darouiche RO. Raad II. Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999;340:1–8. [PubMed] [Google Scholar]
  92. Veenstra DL. Saint S. Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis. JAMA. 1999;281:261–267. [PubMed] [Google Scholar]
  93. Schuerer DJ. Zack JE. Thomas J, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: A before–after trial. Surg Infect. 2007;8:445–454. [PubMed] [Google Scholar]
  94. Camargo LF. Marra AR. Büchele GL, et al. Double-lumen central venous catheters impregnated with chlorhexidine and silver sulfadiazine to prevent catheter colonisation in the intensive care unit setting: A prospective randomised study. J Hosp Infect. 2009;72:227–233. [PubMed] [Google Scholar]
  95. Kalfon P. de Vaumas C. Samba D, et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med. 2007;35:1032–1039. [PubMed] [Google Scholar]
  96. Veenstra DL. Saint S. Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–560. [PubMed] [Google Scholar]
  97. Shorr AF. Humphreys CW. Helman DL. New choices for central venous catheters: Potential financial implications. Chest. 2003;124:275–284. [PubMed] [Google Scholar]
  98. Akiyama H. Okamoto S. Prophylaxis of indwelling urethral catheter infection: Clinical experience with a modified Foley catheter and drainage system. J Urol. 1979;121:40–42. [PubMed] [Google Scholar]
  99. Liedberg H. Lundeberg T. Ekman P. Refinements in the coating of urethral catheters reduces the incidence of catheter-associated bacteriuria: An experimental and clinical study. Eur Urol. 1990;17:236–240. [PubMed] [Google Scholar]
  100. Liedberg H. Lundeberg T. Silver alloy coated catheters reduce catheter-associated bacteriuria. Br J Urol. 1990;65:379–381. [PubMed] [Google Scholar]
  101. Karchmer TB. Giannetta ET. Muto CA, et al. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med. 2000;160:3294–3298. [PubMed] [Google Scholar]
  102. Thibon P. Le Coutour X. Leroyer R. Fabry J. Randomized multi-centre trial of the effects of a catheter coated with hydrogel and silver salts on the incidence of hospital-acquired urinary tract infections. J Hosp Infect. 2000;45:117–124. [PubMed] [Google Scholar]
  103. Bologna RA. Tu LM. Polansky M, et al. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: A multicenter study. Urology. 1999;54:982–987. [PubMed] [Google Scholar]
  104. Riley DK. Classen DC. Stevens LE. Burke JP. A large randomized clinical trial of a silver-impregnated urinary catheter: Lack of efficacy and staphylococcal superinfection. Am J Med. 1995;98:349–356. [PubMed] [Google Scholar]
  105. Srinivasan A. Karchmer T. Richards A, et al. A prospective trial of a novel, silicone-based, silver-coated Foley catheter for the prevention of nosocomial urinary tract infections. Infect Control Hosp Epidemiol. 2006;27:38–43. [PubMed] [Google Scholar]
  106. Schaeffer AJ. Story KO. Johnson SM. Effect of silver oxide/trichloroisocyanuric acid antimicrobial urinary drainage system on catheter-associated bacteriuria. J Urol. 1988;139:69–73. [PubMed] [Google Scholar]
  107. Johnson JR. Roberts PL. Olsen RJ, et al. Prevention of catheter-associated urinary tract infection with a silver oxide-coated urinary catheter: Clinical and microbiologic correlates. J Infect Dis. 1990;162:1145–1150. [PubMed] [Google Scholar]
  108. Saint S. Elmore JG. Sullivan SD, et al. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: A meta-analysis. Am J Med. 1998;105:236–241. [PubMed] [Google Scholar]
  109. Rupp ME. Fitzgerald T. Marion N, et al. Effect of silver-coated urinary catheters: Efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect Control. 2004;32:445–450. [PubMed] [Google Scholar]
  110. Schumm K. Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev. 2008;(2):CD004013. [PubMed] [Google Scholar]
  111. Reiche T. Lisby G. Jørgensen S, et al. A prospective, controlled, randomized study of the effect of a slow-release silver device on the frequency of urinary tract infection in newly catheterized patients. BJU Int. 2000;85:545–549. [PubMed] [Google Scholar]
  112. Huth TS. Burke JP. Larsen RA, et al. Randomized trial of metal care with silver sulfadiazine cream for the prevention of catheter-associated bacteriuria. J Infect Dis. 1992;165:14–18. [PubMed] [Google Scholar]
  113. Daifuku R. Stamm WE. Association of rectal and urethral colonization with urinary tract infection in patients with indwelling catheters. JAMA. 1984;252:2028–2030. [PubMed] [Google Scholar]
  114. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485. [PubMed] [Google Scholar]
  115. Hugonnet S. Eggimann P. Borst F, et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25:1090–1096. [PubMed] [Google Scholar]
  116. Safdar N. Dezfulian C. Collard HR. Saint S. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med. 2005;33:2184–2193. [PubMed] [Google Scholar]
  117. Warren DK. Shukla SJ. Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31:1312–1317. [PubMed] [Google Scholar]
  118. Institute for Healthcare Improvement. http://www.ihi.org. [Jul 29;2011 ]. http://www.ihi.org
  119. Efrati S. Deutsch I. Antonelli M, et al. Ventilator-associated pneumonia: Current status and future recommendations. J Clin Monit Comput. 2010;24:161–168. [PubMed] [Google Scholar]
  120. Doyle A. Fletcher A. Carter J, et al. The incidence of ventilator-associated pneumonia using the PneuX System with or without elective endotracheal tube exchange: A pilot study. BMC Res Notes. 2011;4:92. [PMC free article] [PubMed] [Google Scholar]
  121. Kollef MH. Afessa B. Anzueto A, et al. NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: The NASCENT randomized trial. JAMA. 2008;300:805–813. [PubMed] [Google Scholar]
  122. Lacherade JC. De Jonghe B. Guezennec P, et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: A multicenter trial. Am J Respir Crit Care Med. 2010;182:910–917. [PubMed] [Google Scholar]
  123. Asai T. Shingu K. Leakage of fluid around high-volume, low-pressure cuffs apparatus: A comparison of four tracheal tubes. Anaesthesia. 2001;56:38–42. [PubMed] [Google Scholar]
  124. Berra L. Kolobow T. Laquerriere P, et al. Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: A clinical trial. Intensive Care Med. 2008;34:1030–1037. [PubMed] [Google Scholar]
  125. Rello J. Afessa B. Anzueto A, et al. Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation. Crit Care Med. 2010;38:1135–1140. [PubMed] [Google Scholar]
  126. Olson ME. Harmon BG. Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest. 2002;121:863–870. [PubMed] [Google Scholar]
  127. Rello J. Kollef M. Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med. 2006;34:2766–2772. [PubMed] [Google Scholar]
  128. Palmore TN. Henderson DK. Testing the tube: Assessing silver as a potential “silver bullet” for preventing ventilator-associated pneumonia. Crit Care Med. 2010;38:1220–1221. [PubMed] [Google Scholar]
  129. Afessa B. Shorr AF. Anzueto AR, et al. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest. 2010;137:1015–1021. [PubMed] [Google Scholar]
  130. Kollef MH. Silver P. Murphy DM. Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995;108:1655–1662. [PubMed] [Google Scholar]
  131. Shorr AF. Zilberberg MD. Kollef M. Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumonia. Infect Control Hosp Epidemiol. 2009;30:759–763. [PubMed] [Google Scholar]
  132. Klompas M. Silver-coated endotracheal tubes and patient outcomes in ventilator-associated pneumonia. JAMA. 2008;300:2605. [PubMed] [Google Scholar]
  133. Resar R. Pronovost P. Haraden C, et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf. 2005;31:243–248. [PubMed] [Google Scholar]
  134. Zilberberg MD. Shorr AF. Kollef MH. Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. Crit Care Med. 2009;37:305–309. [PubMed] [Google Scholar]
  135. Wassall MA. Santin M. Isalberti C, et al. Adhesion of bacteria to stainless steel and silver-coated orthopedic external fixation pins. J Biomed Mater Res. 1997;36:325–330. [PubMed] [Google Scholar]
  136. Collinge CA. Goll G. Seligson D. Easley KJ. Pin tract infections: Silver vs uncoated pins. Orthopedics. 1994;17:445–448. [PubMed] [Google Scholar]
  137. Bosetti M. Massè A. Tobin E. Cannas M. Silver coated materials for external fixation devices: In vitro biocompatibility and genotoxicity. Biomaterials. 2002;23:887–992. [PubMed] [Google Scholar]
  138. Massè A. Bruno A. Bosetti M, et al. Prevention of pin track infection in external fixation with silver coated pins: Clinical and microbiological results. J Biomed Mater Res. 2000;53:600–604. [PubMed] [Google Scholar]
  139. Yuenyongviwat V. Tangtrakulwanich B. Prevalence of pin-site infection: The comparison between silver sulfadiazine and dry dressing among open tibial fracture patients. J Med Assoc Thai. 2011;94:566–569. [PubMed] [Google Scholar]
  140. Ogbemudia AO. Bafor A. Edomwonyi E. Enemudo R. Prevalence of pin tract infection: The role of combined silver sulphadiazine and chlorhexidine dressing. Niger J Clin Pract. 2010;13:268–271. [PubMed] [Google Scholar]
  141. Das K. Bose S. Bandyopadhyay A, et al. Surface coatings for improvement of bone cell materials and antimicrobial activities of Ti implants. J Biomed Mater Res B Appl Biomater. 2008;87:455–460. [PubMed] [Google Scholar]
  142. Zhao L. Wang H. Huo K, et al. Antibacterial nano-structured titania coating incorporated with silver nanoparticles. Biomaterials. 2011;32:5706–5716. [PubMed] [Google Scholar]
  143. Khalilpour P. Lampe K. Wagener M, et al. Ag/SiO(x)C(y) plasma polymer coating for antimicrobial protection of fracture fixation devices. J Biomed Mater Res B Appl Biomater. 2010;94:196–202. [PubMed] [Google Scholar]
  144. Sheehan E. McKenna J. Mulhall KJ, et al. Adhesion of Staphylococcus to orthopaedic metals: An in vivo study. J Orthop Res. 2004;22:39–43. [PubMed] [Google Scholar]
  145. Hardes J. von Eiff C. Streitbuerger A, et al. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol. 2010;101:389–395. [PubMed] [Google Scholar]
  146. Hardes J. Ahrens H. Gebert C, et al. Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials. 2007;28:2869–2875. [PubMed] [Google Scholar]
  147. Pupka A. Skora J. Janczak D, et al. In situ revascularisation with silver-coated polyester prostheses and arterial homografts in patients with aortic graft infection: A prospective, comparative, single-centre study. Eur J Vasc Endovasc Surg. 2011;41:61–67. [PubMed] [Google Scholar]
  148. Batt M. Magne JL. Alric P, et al. In situ revascularization with silver-coated polyester grafts to treat aortic infection: Early and midterm results. J Vasc Surg. 2003;38:983–989. [PubMed] [Google Scholar]
  149. Batt M. Jean-Baptiste E. O’Connor S, et al. In-situ revascularisation for patients with aortic graft infection: A single centre experience with silver coated polyester grafts. Eur J Vasc Endovasc Surg. 2008;36:182–188. [PubMed] [Google Scholar]
  150. Ricco JB InterGard Silver Study Group. InterGard silver bifurcated graft: Features and results of a multicenter clinical study. J Vasc Surg. 2006;44:339–346. [PubMed] [Google Scholar]
  151. Larena-Avellaneda A. Russmann S. Fein M. Debus ES. Prophylactic use of the silver-acetate-coated graft in arterial occlusive disease: A retrospective, comparative study. J Vasc Surg. 2009;50:790–798. [PubMed] [Google Scholar]
  152. Tautenhahn J. Meyer F. Buerger T, et al. Interactions of neutrophils with silver-coated vascular polyester grafts. Langenbecks Arch Surg. 2010;395:143–149. [PubMed] [Google Scholar]
  153. Illingworth BL. Tweden K. Schroeder RF. Cameron JD. In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis. J Heart Valve Dis. 1998;7:524–530. [PubMed] [Google Scholar]
  154. Illingworth B. Bianco RW. Weisberg S. In vivo efficacy of silver-coated fabric against Staphylococcus epidermidis. J Heart Valve Dis. 2000;9:135–141. [PubMed] [Google Scholar]
  155. Darouiche RO. Meade R. Mansouri M. Raad II. In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings. J Heart Valve Dis. 1998;7:639–646. [PubMed] [Google Scholar]
  156. Schaff H. Carrel T. Steckelberg JM, et al. Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial. J Heart Valve Dis. 1999;8:131–139. [PubMed] [Google Scholar]
  157. Brutel de la Riviere A. Dossche KM. Birnbaum DE. Hacker R. First clinical experience with a mechanical valve with silver coating. J Heart Valve Dis. 2000;9:123–129. [PubMed] [Google Scholar]
  158. Carrel T. Nguyen T. Kipfer B. Althaus U. Definitive cure of recurrent prosthetic endocarditis using silver-coated St. Jude Medical heart valves: A preliminary case report. J Heart Valve Dis. 1998;7:531–533. [PubMed] [Google Scholar]
  159. Bertrand S. Houel R. Vermes E, et al. Preliminary experience with Silzone-coated St. Jude Medical valves in acute infective endocarditis. J Heart Valve Dis. 2000;9:131–134. [PubMed] [Google Scholar]
  160. Auer J. Berent R. Ng CK, et al. Early investigation of silver-coated Silzone heart valves prosthesis in 126 patients. J Heart Valve Dis. 2001;10:717–723. [PubMed] [Google Scholar]
  161. Kjaergard HK. Tingleff J. Abildgaard U. Pettersson G. Recurrent endocarditis in silver-coated heart valve prosthesis. J Heart Valve Dis. 1999;8:140–142. [PubMed] [Google Scholar]
  162. Ionescu A. Payne N. Fraser AG, et al. Incidence of embolism and paravalvar leak after St. Jude Silzone valve implantation: Experience from the Cardiff Embolic Risk Factor Study. Heart. 2003;89:1055–1061. [PMC free article] [PubMed] [Google Scholar]
  163. Dávila-Román VG. Waggoner AD. Kennard ED, et al. Artificial Valve Endocarditis Reduction Trial Echocardiography Study. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) Echocardiography Study. J Am Coll Cardiol. 2004;44:1467–1472. [PubMed] [Google Scholar]
  164. Schaff HV. Carrel TP. Jamieson WR, et al. Artificial Valve Endocarditis Reduction Trial. Paravalvular leak and other events in Silzone-coated mechanical heart valves: A report from AVERT. Ann Thorac Surg. 2002;73:785–792. [PubMed] [Google Scholar]
  165. Jamieson WR. Fradet GJ. Abel JG, et al. Seven-year results with the St. Jude Medical Silzone mechanical prosthesis. J Thorac Cardiovasc Surg. 2009;137:1109–1115. [PubMed] [Google Scholar]
  166. Grunkemeier GL. Jin R. Im K, et al. Time-related risk of the St. Jude Silzone heart valve. Eur J Cardiothorac Surg. 2006;30:20–27. [PubMed] [Google Scholar]
  167. Herijgers P. Herregods MC. Vandeplas A, et al. Silzone coating and paravalvular leak: An independent, randomized study. J Heart Valve Dis. 2001;10:712–715. [PubMed] [Google Scholar]
  168. Stalenhoef JE. Mellema EC. Veeger NJ. Ebels T. Thrombogenicity and reoperation of the St. Jude Medical Silzone valve: A comparison with the conventional St. Jude Medical valve. J Heart Valve Dis. 2003;12:635–639. [PubMed] [Google Scholar]
  169. Dandekar UP. Baghai M. Kalkat M. Ridley PD. Silzone-coated St. Jude Medical valves: Six-year experience in 46 patients. J Heart Valve Dis. 2007;16:37–41. [PubMed] [Google Scholar]
  170. Butany J. Leask RL. Desai ND, et al. Pathologic analysis of 19 heart valves with silver-coated sewing rings. J Card Surg. 2006;21:530–538. [PubMed] [Google Scholar]
  171. Seipelt RG. Vazquez-Jimenez JF. Seipelt IM, et al. The St. Jude “Silzone” valve: Midterm results in treatment of active endocarditis. Ann Thorac Surg. 2001;72:758–762. [PubMed] [Google Scholar]
  172. Rosenman KD. Moss A. Kon S. Argyria: Clinical implications of exposure to silver nitrate and silver oxide. J Occup Med. 1979;21:430–435. [PubMed] [Google Scholar]
  173. Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res. 2009;30:464–470. [PubMed] [Google Scholar]
  174. Coombs CJ. Wan AT. Masterton JP, et al. Do burn patients have a silver lining? Burns. 1992;18:179–184. [PubMed] [Google Scholar]
  175. Bader KF. Organ deposition of silver following silver nitrate therapy of burns. Plast Reconstr Surg. 1966;37:550–551. [PubMed] [Google Scholar]
  176. Wan AT. Conyers RA. Coombs CJ. Masterton JP. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem. 1991;37:1683–1687. [PubMed] [Google Scholar]
  177. Iwasaki S. Yoshimura A. Ideura T, et al. Elimination study of silver in a hemodialyzed burn patient treated with silver sulfadiazine cream. Am J Kidney Dis. 1997;30:287–290. [PubMed] [Google Scholar]
  178. Lansdown AB. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol. 2007;37:237–250. [PubMed] [Google Scholar]
  179. Trop M. Novak M. Rodl S, et al. Silver-coated dressing Acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma. 2006;60:648–652. [PubMed] [Google Scholar]
  180. Vlachou E. Chipp E. Shale E, et al. The safety of nanocrystalline silver dressings on burns: A study of systemic silver absorption. Burns. 2007;33:979–985. [PubMed] [Google Scholar]
  181. Eldad A. Neuman A. Weinberg A, et al. Silver sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns. 1991;17:430–432. [PubMed] [Google Scholar]
  182. Choban PS. Marshall WJ. Leukopenia secondary to silver sulfadiazine: Frequency, characteristics and clinical consequences. Am Surg. 1987;53:515–517. [PubMed] [Google Scholar]
  183. Fuller FW. Engler PE. Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: A survey. J Burn Care Rehabil. 1988;9:606–609. [PubMed] [Google Scholar]
  184. Gamelli RL. Paxton TP. O’Reilly M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet. 1993;177:115–120. [PubMed] [Google Scholar]
  185. Fraser-Moodie A. Sensitivity to silver in a patient treated with silver sulphadiazine (Flamazine) Burns. 1992;18:74–75. [PubMed] [Google Scholar]
  186. Poon VK. Burd A. In vitro cytotoxity of silver: Implication for clinical wound care. Burns. 2004;30:140–147. [PubMed] [Google Scholar]
  187. Cortese-Krott MM. Münchow M. Pirev E, et al. Silver ions induce oxidative stress and intracellular zinc release in human skin fibroblasts. Free Radic Biol Med. 2009;47:1570–1577. [PubMed] [Google Scholar]
  188. Asharani PV. Hande MP. Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol. 2009;10:65. [PMC free article] [PubMed] [Google Scholar]

Notice Is Given:

This article is posted by Ben Taylor and Utopia Silver Supplements as an exercise of the Freedom of Speech as established in Common/Organic Law and secured by The Bill of Rights/1st Amendment to the Constitution of the  United States of America, as well as The Texas Constitution, Article 1, Sec. 8.

The First Amendment to The Constitution of the United States of America (which is The Supreme Law of the Land) states clearly and unequivocally, “Congress shall make no law respecting [concerning] an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the government for a redress of grievances.”

Texas Constitution, Article 1. Bill of Rights; Sec. 8. Freedom of Speech… “Every person shall be at liberty to speak, write or publish his opinions on any subject, being responsible for the abuse of that privilege; and no law shall ever be passed curtailing the liberty of speech or of the press….”

Pharmakeia is the Greek word from which the terms pharmacy and pharmaceutical are derived. The Bible accurately translates this word into the English language as “witchcraft” or “sorcery”. Therefore, it is our religious belief that the use of drug/pharmakeia/sorcery rather than nutrition as a principal means to optimal health and healthcare is contrary to Biblical truths.

The battle between natural/real healthcare and pharmakeia/sorcery based ”medicine” is a part of the age old conflict of truth vs. deception, good vs. evil, God vs. Satan. It is the core of my religious belief; it is the essence of my spiritual experience in this physical existence.

Any actions taken against me and my livelihood shall be considered as actual Deprivation of my God-given unalienable and non-negotiable Rights; and should damage to me and my livelihood result from any unlawful/non-C0nstitutional actions they will be deemed actionable against that legal fiction entity and its’ directors, agents and/or employees in their individual sentient being capacities in a Court of competent jurisdiction (e.g. The United States Court of Federal Claims) and under all available Common Laws of redress of grievances, as well as Statutory Laws including, but not limited to 42 U.S.C. (Sec. 1983).

Share

Tags: , , , , ,